A clinical trial population should mimic the patient population that will ultimately use the therapy that is being studied. Sounds logical, doesn’t it? Unfortunately, this has not always been the case and there have been negative consequences, such as instances where people with disabilities or of certain racial groups experienced adverse effects to approved drugs that were not tested on “people like them.”
